[ad_1]
For stocks, see Golden Unicorn’s authoritative, professional, timely, and comprehensive analyst research report to help you seize potential thematic opportunities.
Heavy! The national vaccine was approved for commercialization with an effective rate of 86% .The global gap in the supply of the new corona vaccine is highlighted, the stocks of concepts that are expected to continue to benefit are published
Guo Jie original
Another great news for domestic vaccines was released today: the inactivated vaccine for the new coronavirus developed by the Beijing Institute of Biological Products of the Sinopharm Group was approved for commercialization in the United Arab Emirates, with an effective rate of 86%. . Against the background of global supply shortages of new corona vaccines, major domestic vaccine companies are expected to continue to benefit.
The domestic vaccine has an effective rate of 86%
According to the Emirates News Agency, the country’s Ministry of Health and Prevention announced today the registration of the new coronavirus-inactivated vaccine developed by the Beijing Institute of Biological Products of the Sinopharm Group in the country. The UAE Ministry of Health and Prevention and the Abu Dhabi Ministry of Health have reviewed the phase III clinical trial data submitted by Sinopharm. The newly produced inactivated coronavirus vaccine is 86% effective against viral infections and the neutralizing antibody conversion rate is 99%. It can prevent 100% of moderate and severe cases of new coronary pneumonia, and relevant studies have not found serious safety in the vaccine. Hidden dangers.
It is understood that the two inactivated vaccines from the Beijing Institute of Biologicals and the Wuhan Institute of Biologicals under Sinopharm Sinopharm are currently in phase III clinical trials in ten countries, including the United Arab Emirates, Paris, Jordan, Peru, Argentina and Egypt. The progress is widely recognized internationally. Today, dozens of countries have submitted new crown vaccine requirements to Sinopharm Group Sino Biotech.
Spurred on by the good news, todaySinopharmThe late trading limit reached 2.69 billion yuan, and the share price has doubled during the year.
Highlights of the global gap in the supply of the new corona vaccine
Recently, it was reported that the current President of the United States, Trump, signed an executive order on the 8th to ensure that the vaccination needs of 330 million Americans are met before local vaccine suppliers can supply vaccines to other countries. . US officials revealed that under this new order, the timing of subsequent US vaccine assistance provided by the United States will be questionable and is expected to begin in the second quarter.
However, in response to this incident, some analysts believe that after Biden takes office on January 20 next year, a new vaccine distribution policy can be formulated, but at least until January 20, countries foreigners will not receive a US vaccine. The gap in vaccine supply is highlighted.
Although many countries are developing vaccines to compete against the new coronavirus, not many have a clue.
“
China’s vaccines ranks first in the world. As of December 2, there are 214 investigational vaccines worldwide and 51 have entered clinical trials, of which 14 are from China; 14 have entered phase III clinical trials and China had 6.
“
In early December, Wang Junzhi, deputy director of the Vaccine Research and Development Task Force of the Scientific and Academic Research Group of the Chinese Academy of Engineering, delivered a speech on “Progress of research and development of anti-drugs and vaccines. new coronary pneumonia “at the Eighth World Congress of Integrated Western and Traditional Chinese Medicine. The inactivated vaccine was approved for commercialization. “
9.6 billion doses of COVID-19 vaccine reserved worldwide
Vaccines are in high demand
Currently, many countries, including China, have successively launched vaccination plans to achieve a new vaccination crown. According to statistics from Duke University, 30 countries, regions and alliances around the world plan to buy a total of 9.6 billion doses of the new corona vaccine, of which 6.4 billion doses are clear purchase orders, and another 3.2 billion doses are in acquisition negotiation or as preliminary orders. Extend the purchase quota reservation.
The demand for the new corona vaccine is unimaginable:
“
According to an article written by Dr. Du Heng of the Gates Foundation, experts at Johns Hopkins University estimate that herd immunity requires that between 70% and 90% of the population be immune to the virus. Based on the world population of 7.5 billion, between 5.25 and 675 million are needed. People are immunized. Considering that sometimes two doses of vaccines are immune, at least 10 billion doses of the new corona vaccine are needed globally.
“
Strong
Major companies will continue to benefit
Industrial valuesIt is believed that in the future, as access barriers to the domestic vaccine market increase and the concentration of the industry continues to increase, the major vaccine companies will fully benefit, stable cash flow can support the simultaneous advancement of multiple pipes and large-scale production capacity will be the market share. Favorable warranty, a strong national distribution network and a sales system accelerate the increase in product penetration.
Yuekai Securities believes that taking into account the domestic vaccine production capacity and export factors in 2021, companies at the forefront of research and development of new corona vaccines will continue to benefit in the future. It is estimated that in 2021, domestic vaccines may cover 900 to 1 billion people. Furthermore, in terms of the number of orders abroad, domestic companies have signed orders for more than 600 million doses with Brazil and other countries in 2021, which means that domestic vaccines can cover up to 600-700 million residents. nationals in 2021, and there is still plenty of room for the new crown domestic vaccine market. .
Since the beginning of winter, the global epidemic has continued to spread and local cases have begun to be diagnosed in many parts of the country. Good news about the progress of layered vaccine research and development has been frequent, and the vaccine industry chain has once again attracted public attention. Securities Times · Databao ranked 19 vaccine concept stocks. Since November, the share prices of these 19 concept stocks have fallen by an average of 1.74%, underperforming significantly than the market. The main winners include Sinopharm,Jingshan Light Machine、Guanhao Bio、Liaoning ChengdaWait. Since December, these 19 stocks have risen an average of 3.98%. Sinopharm,Kangtai Bio、Zhifei、Wantai BioOther stocks rose more.
Judging by the recent inflow of funds from the north, since December, 6 stocks have received net purchases of funds from the north, namelyBiological actions、Watson Bio、Fosun Pharma、Anke Bio、Changchun High TechAnd Sinopharm shares. Among them, the net purchase amount of Beijing funds from Bio-Stocks is the largest.
Disclaimer: All content of the Databank information does not constitute investment advice. The stock market is risky and investing must be cautious.
Sina Statement: This news is a reprint by Sina Cooperative Media. Posting this article on Sina.com for the purpose of conveying more information does not mean that I agree with their views or confirm their description. The content of the article is for reference only and does not constitute investment advice. Investors trade accordingly at their own risk.
Massive information, accurate interpretation, all in the Sina Finance APP
Editor in Charge: Yang Hongbu
